Inmed reports second quarter fiscal 2025 financial results and provides business update

Vancouver, british columbia--(newsfile corp. - february 12, 2025) - inmed pharmaceuticals inc. (nasdaq: inm) ("inmed" or the "company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today reports financial results for the second quarter of the fiscal year 2025 which ended december 31, 2024. the company's full financial statements and related md&a for the first quarter ended december 31, 2024, are available at www.inmedpharma.com, www.sedar.com and at www.sec.gov.
INM Ratings Summary
INM Quant Ranking